In vivo Markers of inflammatory response in recent-onset schizophrenia: A combined study using [11C]DPA-713 PET and analysis of CSF and plasma

Translational Psychiatry

Volumn 6, Issue 4, 2016, Pages 1-8

  Coughlin, J M ^a   Wang, Y ^a   Ambinder, E B ^a   Ward, R E ^a   Minn, I ^a   Vranesic, M ^a   Kim, P K ^a   Ford, C N ^a   Higgs, C ^a   Hayes, L N ^a   Schretlen, D J ^a   Dannals, R F ^a   Kassiou, M ^b   Sawa, A ^a   Pomper, M G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; INTERLEUKIN 6; MARKER; N,N DIETHYL 2 (4 METHOXYPHENYL) 5,7 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE 3 ACETAMIDE C 11; NEUROLEPTIC AGENT; TRACER; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; BIOLOGICAL MARKER; N,N-DIETHYL-2-(2-(4-METHOXYPHENYL)-5,7-DIMETHYL-PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-ACETAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIA; HUMAN; IN VIVO STUDY; INFLAMMATION; MALE; PLASMA; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; SUBCORTEX; ADOLESCENT; BLOOD; BRAIN; BRAIN MAPPING; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES; YOUNG ADULT;

ACETAMIDES; ADOLESCENT; ADULT; BIOMARKERS; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; INFLAMMATION; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIMIDINES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84992417287     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.40     Document Type: Article

References (60)

1. Brown AS. Further evidence of infectious insults in the pathogenesis and pathophysiology of schizophrenia. Am J Psychiatry 2011;168:764-766.
2. Horvath S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry 2014;75:316-323.
3. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-808.
4. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671.
5. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medicationnaive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 2014;155:101-108.
6. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 2013;73:951-966.
7. Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry 2016;21:10-28.
8. Owen MJ, Mortensen PB, Sawa A. Schizophrenia. Lancet 2016 (in press).
9. Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 2014;75:292-299.
10. Freidin M, Bennett MV, Kessler JA. Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci USA 1992;89:10440-10443.
11. Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev 1997;10:742-780.
12. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-694.
13. Dolle F, Luus C, Reynolds A, Kassiou M. Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Curr Med Chem 2009;16:2899-2923.
14. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther 2008;118:1-17.
15. Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Dolle F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging 2012;3:111-119.
16. Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia 2013;61:10-23.
17. Owen DR, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol 2011;101:19-39.
18. Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging 2008;35:2304-2319.
19. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010;13:943-950.
20. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull 2015;41:85-93.
21. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11) C]PBR28 PET brain imaging study. Am J Psychiatry 2016;173:44-52.
22. Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A. Kinetic modeling without accounting for the vascular component impairs the quantification of [(11) C]PBR28 brain PET data. J Cereb Blood Flow Metab 2014;34:1060-1069.
23. Coughlin JM, Ishizuka K, Kano SI, Edwards JA, Seifuddin FT, Shimano MA et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 2013;18:10-11.
24. Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 2014;40:963-972.
25. Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med 2009;50:1276-1282.
26. Coughlin JM, Wang Y, Ma S, Yue C, Kim PK, Adams AV et al. Regional brain distribution of translocator protein using [(11) C]DPA-713 PET in individuals infected with HIV. J Neurovirol 2014;20:219-232.
27. Coughlin JM, Wang Y, Munro CA, Ma S, Yue C, Chen S et al. Neuroinflammation and brain atrophy in former NFL players: an in vivo multimodal imaging pilot study. Neurobiol Dis 2014;74:58-65.
28. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute: New York, NY, USA, 2002.
29. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789-794.
30. Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO et al. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res 2012;142:77-82.
31. Miller DD, Arndt S, Andreasen NC. Alogia, attentional impairment, and inappropriate affect: their status in the dimensions of schizophrenia. Compr Psychiatry 1993;34:221-226.
32. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-262.
33. Ojeda N, Pena J, Schretlen DJ, Sanchez P, Aretouli E, Elizagarate E et al. Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophr Res 2012;135:72-78.
34. Parmenter BA, Testa SM, Schretlen DJ, Weinstock-Guttman B, Benedict RH. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2010;16:6-16.
35. Testa SM, Winicki JM, Pearlson GD, Gordon B, Schretlen DJ. Accounting for estimated IQ in neuropsychological test performance with regression-based techniques. J Int Neuropsychol Soc 2009;15:1012-1022.
36. Schretlen DJ, Winicki JM, Meyer SM, Testa SM, Pearlson GD, Gordon B. Development, psychometric properties, and validity of the hopkins adult reading test (HART). Clin Neuropsychol 2009;23:926-943.
37. Thominiaux C, Dolle F, James ML, Bramoulle Y, Boutin H, Besret L et al. Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C]methyl triflate. Appl Radiat Isot 2006;64:570-573.
38. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000;27:627-630.
39. Rahmim A, Lenox M, Reader AJ, Michel C, Burbar Z, Ruth TJ et al. Statistical listmode image reconstruction for the high resolution research tomograph. Phys Med Biol 2004;49:4239-4258.
40. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001;49:487-499.
41. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in firstepisode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-518.
42. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006;63:139-149.
43. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009;50:1801-1807.
44. Coughlin JM, Wang Y, Ma S, Yue C, Kim PK, Adams AV et al. Regional brain distribution of translocator protein using [C]DPA-713 PET in individuals infected with HIV. J Neurovirol 2014;20:219-232.
45. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
46. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-1539.
47. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2014.
48. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013;18:206-214.
49. Scarf AM, Kassiou M. The translocator protein. J Nucl Med 2011;52:677-680.
50. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ. Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 1998;55:540-546.
51. Schnieder TP, Dwork AJ. Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 2011;69:134-139.
52. De Picker L, Morrens M, Sabbe BGC, Gentleman S, Nicoll JAR, Boche D. EPA-0759 - Multi-immunostaining for microglial activation in schizophrenia. Eur Psychiatry 2014;29(Supplement 1):1.
53. Banati RB, Myers R, Kreutzberg GW. PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 1997;26:77-82.
54. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012;13:293-307.
55. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res 2015;161:4-18.
56. Danovich L, Veenman L, Leschiner S, Lahav M, Shuster V, Weizman A et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 2008;18:24-33.
57. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 1995;57:1011-1026.
58. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
59. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008;28:13957-13966.
60. Tezuka T, Tamura M, Kondo MA, Sakaue M, Okada K, Takemoto K et al. Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis. Neurobiol Dis 2013;59:63-68.